

**Listing of the Claims:**

Please amend claim 68 as follows:

1-67. (Cancelled).

68. (Presently amended) A method for stimulating an immune response in an individual, said method comprising administering an antigen through a C-type lectin receptor on an antigen presenting cell of said individual, wherein said antigen comprises a glycoconjugate comprising at least one non-sialylated Lewis x antigen.

69. (New) A method according to claim 68, wherein said antigen is a peptide or glycolipid capable of being presented in the context of MHC class I or class II or C1b.

70. (New) A method according to claim 69, wherein said antigen is selected from the group consisting of a pathogen antigen, a tumor antigen, a cell associated receptor antigen, an autoimmune antigen, a self-antigen and a C-type lectin binding part thereof.

71. (New) A method according to claim 69, wherein said antigen is a pathogen or a tumor antigen.

72. (Withdrawn) A method according to claim 71, wherein said pathogen is selected from the group consisting of a virus, a fungus, and a bacterium.

73. (Withdrawn) A method according to claim 71, wherein said pathogen is a mycobacterium or a parasite.

74. (Withdrawn) A method according to claim 71, wherein said pathogen is selected from the group consisting of a Human Immunodeficiency Virus, a *Helicobacter*, a *Neisseria meningitidis*, a *Leishmania*, a *Schistosoma*, a *Klebsiella*, a probiotic *Lactobacillus*, Hepatitis C Virus, a Herpes simplex virus and an Ebola virus.

75. (New) A method according to claim 68, wherein said C-type lectin receptor is DC-SIGN.

76. (New) A method according to claim 68 for the treatment of an individual suffering from a cancer, an autoimmune disease or a transplantation related disease.